Business Context and Reporting Period
Company: MacroGenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2015
Event: Consummation of a strategic collaboration and investment agreement with Janssen Biotech, Inc. and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).
Key Financial Metrics and Transaction Terms
This filing details a transaction rather than periodic financial performance. Key financial terms include:
- Upfront License Fee: $50 million payable by Janssen to MacroGenics.
- Equity Investment: $75 million invested by JJDC for 1,923,077 new shares of common stock at $39.00 per share.
- Potential Milestone Payments: Up to $575 million contingent on successful development, regulatory approval, and commercialization.
- Royalties: Double-digit royalties on global net sales.
- Profit Sharing Option: MacroGenics may fund a portion of clinical development to receive a share of net profits from U.S. and Canada sales in lieu of certain milestones and royalties.
Note: The filing does not provide current revenue, profit, cash flow, or debt figures for the company.
Material Changes and Strategic Developments
The primary material change is the entry into definitive agreements regarding the product candidate MGD011:
- Product Focus: MGD011 utilizes the Dual-Affinity Re-Targeting (DART) platform to target CD19 and CD3 for the treatment of leukemias and lymphomas.
- Development Responsibility: Janssen assumes full responsibility for development following the submission of the investigational new drug application (IND).
- Current Status: MGD011 is in pre-clinical development.
- Commercial Rights: MacroGenics retains the option to co-promote MGD011 in the U.S.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The transaction provides immediate capital and transfers development risk to Janssen while retaining significant upside potential through milestones and royalties.
Risks and Termination Provisions:
- Termination by Janssen: Janssen may terminate the Collaboration Agreement with 180 days' written notice, or immediately in cases of safety concerns or MacroGenics' bankruptcy.
- Termination by MacroGenics: MacroGenics may terminate if Janssen challenges certain patents.
- Investor Restrictions: JJDC has agreed to hold shares for a specified period and vote in accordance with Board recommendations, with restrictions on acquiring additional equity for a certain time.
Investor Verification Checklist
- Verify the exact terms of the "double-digit" royalty rates and the specific profit-sharing percentages available under the option to fund clinical development.
- Confirm the timeline for the submission of the investigational new drug application (IND) for MGD011, as this triggers Janssen's full development responsibility.
- Review the specific milestones required to unlock the potential $575 million in payments.
- Check the lock-up period duration for JJDC's shares and any specific conditions for early release.
- Monitor future filings (Form 10-K) for the full text of the Collaboration and Stock Purchase Agreements.